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Mild Cognitive Impairment (MCI)Amyloid imaging with positron emission tomography (PET) is presently used in Alzheimer's disease (AD) re-
search. In this study we investigated the possibility to use early frames (ePIB) of the PIB scans as a rough
index of CBF by comparing normalised early PIB values with cerebral glucose metabolism (rCMRglc). PIB-
PET and FDG-PET were performed in 37 AD patients, 21 subjects with mild cognitive impairment (MCI)
and 6 healthy controls (HC). The patients were divided based on their PIB retention (amyloid load) as either
PIB positive (PIB+) or PIB negative (PIB−). Data of the unidirectional inﬂux K1 from a subset of the subjects
including 7 AD patients and 3 HC was used for correlative analysis. Data was analysed using regions of inter-
est (ROI) analysis. A strong, positive correlation was observed across brain regions between K1 and ePIB
(r=0.70; p≤0.001). The ePIB values were signiﬁcantly lower in the posterior cingulate (p≤0.001) and the
parietal cortices (p=0.002) in PIB+ subjects compared to PIB−, although the group difference were stronger
for rCMRglc in cortical areas (p≤0.001). Strong positive correlations between ePIB and rCMRglc were ob-
served in all cortical regions analysed, especially in the posterior cingulate and parietal cortices (p≤0.001).
A single dynamic PIB-PET scan may provide information about pathological and functional changes (amyloid-
osis and impaired blood ﬂow). This might be important for diagnosis of AD, enrichment of patients in clinical
trials and evaluation of treatment effects. This article is part of a Special Issue entitled: Imaging Brain Aging
and Neurodegenerative disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
PET imaging with amyloid tracers such as [11C] N-methyl [11C] 2-
(4′methylaminophenyl)-6-hydroxy-benzothiazole (PIB) allows mea-
surement of high cerebral amyloid-ß deposition in AD and thereby
discriminating AD patients from healthy controls [1,2]. High amy-
loid-ß load has also been demonstrated by PIB in patients with mild
cognitive impairment (MCI) that later converts to AD [3,2]. It hasAD, Alzheimer's disease; CBF,
I, Mild cognitive impairments;
nation; PIB, N-methyl [11C] 2-
Rglc, regional cerebral meta-
Brain Aging and Neurodegen-
zheimer Neurobiology Center,
or, 141 86 Stockholm, Sweden.
rg).
l rights reserved.also been shown that PIB-PET may differentiate AD patients from pa-
tients with frontotemporal lobe dementia [4–6] or Parkinson's dis-
ease [4,7,8] whilst patients with dementia with Lewy bodies may
show high but variable PIB retention [4,8,9]. Recently several amyloid
tracers labelled with 18F such as ﬂorbetaben,ﬂorbetapir and ﬂuteme-
tamol have been developed suitable for clinical PET facilities [2,10].
PET imaging of cerebral metabolic rate of glucose (CMRglc) using
2-[18F]-2-deoxy-D-glucose (FDG) has been used to detect functional
changes in AD with reduced FDG uptake especially in the temporal,
parietal and posterior cingulate cortices [11,12]. Similar results have
been obtained in studies of changes in cerebral blood ﬂow (CBF) in
AD patients [13–16]. Although both CMRglc and CBF have been sug-
gested to be able to predict conversion from MCI to AD, FDG-PET
seems to be somewhat superior [17,18]. One study however directly
compared the diagnostic accuracy of CMRglc measured with FDG-
PET and CBF measured by IMP-SPECT and observed no signiﬁcant dif-
ference between the two measurements in diagnostic accuracy, and
the twomeasurements correlated signiﬁcantly in the parietotemporal
cortex and posterior cingulate cortex/precuneus [16]. This result sug-
gests that the two functional estimates, rCMRglc and CBF, are related
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imaging as a functional measurement of CBF.
The possibility to combine pathological and functional measure-
ments would improve the accuracy in AD diagnostics and increase
our understanding of neurodegenerative processes occurring in the
brain of AD patients. Although it is possible to perform PIB- and
FDG-PET scans in a patient at the same day [1] this procedure is time
consuming, expensive, and demanding on the patient. It would be an
advantage for clinical as well as research purposes to obtain, from a
single PET scan, both pathological and functional measurements.
In an earlier study we combined data from rate constant K1 for
unidirectional inﬂux across the brain barrier with data for PIB reten-
tion. We demonstrated dynamic PIB-PET data by using a kinetic
model, with one reversible and one irreversible tissue compartment
and three rate constants, to investigate the PIB net accumulation
(Kacc) and unidirectional inﬂux (K1) across the blood brain barrier
(BBB) in HC and AD patients [19]. We compared the results with
the ratio between the retention in a target and reference region in a
late interval (PIB), in HC and AD patients from previous studies [1].
The parameter Kacc and the PIB were found to have similar regional
distributions. The rate constant K1 for PIB was found to be compara-
tively large, demonstrating high extraction of PIB into brain and indi-
cating that this time interval following tracer administration might
reﬂect CBF [19]. We further showed in a controlled PET study of a
rhesus monkey that K1 correlated well with CBF measured with
[15O]H2O which is the golden standard measurement of CBF, suggest-
ing that unidirectional inﬂux rate constant K1 of PIB as a good index of
CBF [19]. The aim of the present study was to investigate the possibil-
ity to replace K1 by a simpliﬁed index of PIB uptake in the early time
interval after tracer administration. Data from the early frames of the
dynamic PIB (ePIB) was compared with K1 and rCMRglc data in a set
of AD patients, MCI patients and age matched healthy controls.
2. Material and methods
2.1. Subjects
PET data was obtained from 37 AD patients, 21 MCI patients and 6
healthy controls (HCs). The demographic data of the patients is
shown in Table 1. All patients were recruited from the Department
of Geriatric Medicine, Karolinska University Hospital Huddinge,
Stockholm, Sweden. All AD and MCI patients had undergone a com-
prehensive assessment of memory problems including physical ex-
amination, evaluation of neurological and psychiatric status, blood
analysis including apolipoprotein E (ApoE) genotyping, electroen-
cephalography, magnetic resonance imaging, and/or single photon
computed tomography (SPECT), cerebrospinal ﬂuid analysis, and cog-
nitive and neuropsychological testing.
The AD patients were diagnosed as probable AD according to the
criteria of the National Institute of Neurological and Communication
Disorders, Alzheimer's Disease and Related Disorders Association
(NINCDS-ADRDA) [20]. None of the HCs had a history of a medical
or neurological disease or substance abuse, and all scored normally
on neuropsychological testing. The diagnosis of MCI was based upon
the modiﬁed Petersen criteria [21,22]. All included subjects gaveTable 1
Demographic data of patients with Alzheimer's disease (AD), mild cognitive impair-
ment (MCI) and healthy controls (HC).
AD MCI HC
Age 67.5±9.2 63.3±7.8 69.0±7.2
Gender (male/female) 17/20 8/13 3/3
MMSE 23.7±4.0⁎⁎⁎ 28.2±1.4 30±0
ApoE-ε4 carriers 25 14 –
PIB+/PIB− 32/5 11/10 1/5
⁎⁎⁎ pb0.001 (AD vs MCI).written consent to participate in the study. The Ethics Committees
of Uppsala University, the Karolinska Institute and the Isotope Com-
mittee at Uppsala Academic Hospital approved the study.
A subset of data was used from the patients mentioned above, in
which arterial sampling and kinetic modelling was performed, com-
prising of 7 AD patients with a mean age of 66±10, and 3 healthy
controls with a mean age of 57±31 (21, 72 and 77 years old).
PIB-PET and FDG-PET data from the AD patients, MCI patients and
HC have been used in previous publications [1,3,23]
2.2. PET scanning and data analysis
The subjects underwent PET examinations with PIB and FDG at
Uppsala PET center, Uppsala, Sweden. Production of FDG and PIB
was carried out according to good manufacturing standards at Uppsa-
la PET center, and the synthesis of PIB was performed as previously
described [1,24]. The tracer doses of PIB and FDG, and the scanner
protocol for transmissions, emissions and reconstructions, as well as
image pre-processing have previously been published [1,3].
Quantitative data of PIB retention and cerebral glucose metabo-
lism (CMRglc) were generated as described in detail in previous stud-
ies [3,23]. Data from the early frames of the PIB (ePIB) were generated
by summation of the frames from the ﬁrst 6 min. Standard uptake
values (SUV) were calculated and the data from the early frames
(6 min) was normalised to the reference region in the cerebellar cor-
tex using data from the same time interval (ﬁrst 6 min). To account
for global differences between patients the CMRglc data was normal-
ised to the pons, a region with quite stable glucose metabolism during
disease progression [25]. Modelling of the data rendering the K1 pa-
rameter has been described in detail elsewhere [19].
The set of regions of interest (ROIs) used in statistical analysis has
previously been described in detail [1,26]. Data from the frontal, pari-
etal, temporal and primary visual cortices, posterior cingulate cortex,
striatum, thalamus and white matter were included in the statistical
analysis comparing patient groups. For correlative analysis across re-
gions between K1 and ePIB the same set of ROIs were used with some
exceptions: posterior cingulate cortex was not included and a ROI at
the level of thalamus including the whole brain was included.
Based on the PIB retention level two groupswere created, onewith
high PIB retention (PIB+) and one with low PIB retention (PIB−). The
cut-off level used was calculated as the mean plus one standard devi-
ation above the level of the healthy controls and has been described
before [3]. The cut-off level was calculated to 1.6, a number that is cor-
responding to what have been described in other PIB-PET studies
[27–29]. The numbers of PIB+ and PIB− patients are shown in Table 1.
Analyses of group differences were conducted by using two-tailed
Student's t-tests. Correlation analyses were conducted, using Pear-
son's product moment correlation coefﬁcient r. No correction for mul-
tiple comparisons was done due to the explorative nature of this pilot
study.
3. Results
3.1. Group differences in clinical parameters
The demographical and clinical parameters are described in
Table 1. The AD patients showed a signiﬁcant lower MMSE score com-
pared to MCI patients. For further analysis the subjects were divided
in PIB+ and PIB− patients as described above.
3.2. Relationship between K1 and ePIB
Correlation analyses were performed across brain regions to eval-
uate the relationship between K1 and ePIB. A signiﬁcant positive cor-
relation was found between K1 and ePIB as shown in Fig. 1 (r=0.70,
pb0.001).
e
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Fig. 1. Correlation across brain regions between the unidirectional inﬂux K1 and ePIB in
7 AD patients and 3 healthy controls. Included areas are frontal, parietal and temporal
and primary visual cortices, putamen, thalamus, white matter and a ROI comprising the
whole cortex at the level of thalamus.
Fig. 2. Example of one AD patient showing high cortical PIB retention and clear parietal
deﬁcits in both relative cerebral metabolic rate of glucose (rCMRglc) measured by FDG-
PET and ePIB (cerebral blood ﬂow).
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The PIB+ group showed signiﬁcantly higher PIB retention than
the PIB− group dependent in all brain regions on the division of the
material (Table 2). Signiﬁcantly lower values of ePIB were solely ob-
served in the PIB+ group compared to the PIB− group in the poste-
rior cingulate cortex and parietal cortex (Table 2). The PIB+ group
also showed signiﬁcantly lower rCMRglc compared to PIB− group
in all cortical brain regions as well as the striatum and thalamus but
not in the white matter (Table 2).3.4. Cerebral glucose metabolism (FDG) vs cerebral blood ﬂow (ePIB)
The individual patients showed reduction in rCMRglc and ePIB up-
take at visual inspection as exempliﬁed in Fig. 2.
A positive correlation was found between rCMRglc and ePIB in all
regions analysed (Table 3 and Fig. 3). The strongest correlations were
found in the posterior cingulate cortex, parietal cortex, frontal cortex,
primary visual cortex, and white matter respectively (Table 3 and
Fig. 3).3.5. Cerebral blood ﬂow (ePIB) and cerebral glucose metabolism (FDG)
compared with PIB retention
The cortical brain areas showed less correlation between ePIB and
PIB retention compared to subcortical brain regions such as the stria-
tum, and thalamus (Table 3).Table 2
PIB retention, ePIB (early frames of PIB), and rCMRglc in patients with Alzheimer's disease
PIB ePIB
ROI PIB− PIB+ PIB− vs PIB+
p-level
PIB−
Striatum 1.27±0.12 2.16±0.44 >0.001 1.09±0.10
Post cing 1.22±0.16 2.33±0.36 >0.001 1.03±0.09
WhM 1.70±0.23 1.87±0.24 0.009 0.54±0.08
Frontal ctx 1.17±0.16 2.30±0.41 >0.001 0.95±0.07
Parietal ctx 1.30±0.11 2.25±0.35 >0.001 0.96±0.07
Prim vis ctx 1.14±0.10 1.84±0.39 >0.001 1.07±0.11
Thalamus 1.36±0.16 1.78±0.31 >0.001 1.15±0.10
Temporal ctx 1.22±0.10 1.77±0.27 >0.001 0.78±0.05
Post cing = posterior cingulate cortex, WhM = white matter, Prim vis = primary visual, cSigniﬁcant negative correlations between rCMRglc and PIB reten-
tion were observed in the posterior cingulate cortex, parietal and
frontal cortices (pb0.001) (Table 3).4. Discussion
Molecular imaging has advanced our knowledge of the time
course of events leading to AD. Amyloid imaging has shown high ac-
cumulation of amyloid in very early state of disease and precedes
functional changes measured as reduction in cerebral glucose metab-
olism and cognitive impairment [2]. Functional imaging using FDG-
PET is clinically used to differentiate between different forms of de-
mentia with speciﬁc decline in glucose metabolism in parietotem-
poral regions and posterior cingulate cortex [11,30] in AD patients.
The same speciﬁc areas have shown decline in CBF [13]. It has also
been indicated that there is a clear relationship between declines in
glucose metabolism found with FDG-PET and decline in blood ﬂow
in AD patients [16]. The possibility to acquire functional and patho-
logical information from a single dynamic PET scan might be valuable
in the diagnosis of AD and in the evaluation of anti-amyloid treatment
strategies.
In this study, we demonstrated that the unidirectional inﬂux K1
(reﬂecting the CBF) was signiﬁcantly related to the ePIB ratio. This re-
sult supported our previous ﬁndings that K1 is a good estimation of
CBF [19], nevertheless ePIB should be appreciated as an estimation
of CBF. These justiﬁed further exploration of the relationship between
ePIB ratio, rCMRglc and CBF.
Pathological changes produced by amyloid depositions were mea-
sured with late PIB retention (PIB). Increased PIB retention was found
in almost all AD patients, about half of the MCI patients and in one HC,
which is supported by previous studies [1,3,4,31]. PIB+ MCI patients
will most likely convert to AD in contrast to PIB−MCI patients [3]. In(AD), mild cognitive impairment (MCI) and healthy controls (HC).
rCMRglc
PIB+ PIB− vs PIB+
p-level
PIB− PIB+ PIB− vs PIB+
p-level
1.11±0.10 0.490 2.00±0.30 1.81±0.26 0.012
0.91±0.12 >0.001 2.04±0.44 1.40±0.36 >0.001
0.53±0.08 0.598 0.88±0.21 0.81±0.16 0.187
0.93±0.07 0.236 1.74±0.31 1.48±0.21 >0.001
0.87±0.11 0.002 1.75±0.29 1.25±0.32 >0.001
1.06±0.11 0.556 1.84±0.29 1.59±0.27 0.002
1.15±0.09 0.898 1.76±0.21 1.59±0.23 0.006
0.76±0.06 0.234 1.29±0.20 1.11±0.15 >0.001
tx = cortex.
Table 3
Correlation between rCMRglc vs ePIB, ePIB vs PIB and rCMRglc vs PIB in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI) and healthy controls (HC).
ROI rCMRglc vs ePIB (n=61) ePIB vs PIB (n=62) rCMRglc vs PIB (n=63)
Striatum r=0.27; p=0.035 r=0.33; p=0.008 r=−0.18; p=0.152
Posterior cingulate cortex r=0.74; pb0.001 r=−0.26; p=0.045 r=−0.53; pb0.001
White matter r=0.63; pb0.001 r=0.20; p=0.127 r=−0.20; p=0.124
Frontal cortex r=0.42; p=0.001 r=−0.02; p=0.879 r=−0.41; p=0.001
Parietal cortex r=0.74; pb0.001 r=−0.27; p=0.032 r=−0.51; pb0.001
Primary visual cortex r=0.44; pb0.001 r=0.10; p=0.453 r=−0.21; p=0.096
Thalamus r=0.17; p=0.190 r=0.35; p=0.006 r=−0.26; p=0.041
Temporal cortex r=0.39; p=0.002 r=0.10; p=0.421 r=−0.22; p=0.083
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ly) younger that the AD patients. The PIB+ MCI patients may only
underestimate their PIB retention at early stage of MCI when progres-
sion to late stages of MCI is expected [32]. Early frames of the samee
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Fig. 3. Scatter plots of cerebral metabolic rate of glucose (rCMRglc) measured by FDG-
PET and ePIB (cerebral blood ﬂow). Correlation is found between rCMRglc and ePIB in
all areas analysed and shown here is the posterior cingulate cortex (A), the frontal cor-
tex (B) and the parietal cortex (C).PIB-scan were compared with the glucose metabolism in AD patients,
MCI patients and HC. Signiﬁcant positive correlation between ePIB
and the rCMRglc was demonstrated in all analysed areas, suggesting
that early PIB frames might be used as a rough index of CBF. Due to
the exploratory nature of the paper no corrections for multiple com-
parisons were performed and single correlations therefore need to
be addressed with caution and rather the general patterns will be dis-
cussed. Nor did we study correlations in subgroups and further re-
search needs to be done to address the relationship between these
functional parameters.
The rCMRglc however, seems to discriminate better than ePIB be-
tween PIB+ and PIB− patients. This could be explained by the fact
that FDG-PET measures not only blood ﬂow but neuronal and synap-
tic activity and a decrease indicates neuronal dysfunction [33], whilst
decrease in CBF is a more indirect measurement of impairment
caused by decreased demand of blood supply due to cerebral atrophy
[34]. Evaluation of prognostic accuracy fell outside the scope of this
paper and coming studies need to compare the prognostic accuracy
of ePIB, CMRglc and CBF measured with conventional methods. How-
ever, the posterior cingulate cortex and the parietal cortex were areas
that FDG-PET and ePIB-PET discriminated similarly between PIB+
and PIB− patients. A recent paper showed that the posterior cingu-
late cortex was the only hypometabolic area in all MCI subjects inves-
tigated in that study 35]. Hypometabolism or reduced CBF in
parietotemporal regions and/or posterior cingulate cortex has been
demonstrated to have predictor values in the conversion from MCI
to AD [17,36,37]. It is valuable to combine these measurements with
others, such as memory impairment 37,38] and structural imaging
[39]. Multi-tracer PET studies can contribute to reveal the complex
neuropathological processes of AD [2,40,41]. PIB retention seems to
follow a different time course compared to that observed for cerebral
glucose metabolism, cognition and brain atrophy [2,42]. Li et al. [43]
suggested that the combination of data from PIB retention in the
middle frontal gyrus with CMRglc in the hippocampus increases the
correct classiﬁcation of MCI patients vs HC from 75% and 85% respec-
tively to 90% Lowe et al. [44] recently presented data indicating that
PIB PET is better than FDG PET in discriminating between amnestic
MCI and non-amnestic MCI [44]. The early and late frame ratios of
PIB acquisitions provide complementary information that might im-
prove the diagnostic power of PET. Early PIB uptake has been reported
to positively correlate with MMSE score [45]. Furthermore Rostomian
et al. [46] recently observed that early frames of PIB is slightly better
than FDG in correctly classifying AD patients whilst both PET ligands
are equally correct in classifying patients with frontotemporal lobe
dementia [45].
In this study, we observed a signiﬁcant correlation between
rCMRglc and PIB retention in a data set from AD, MCI patients, and
healthy controls This observations is in accordance with other studies
suggesting some relation between pathological and functional pa-
rameters [1,47,48]. Only a few areas showed signiﬁcant correlation
between late PIB retention and ePIB and those included the thalamus
and striatum. Nevertheless the r-values are really low witnessing of a
big variance in the material and more research would be needed be-
fore drawing any further conclusions.
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with larger number of patients are necessary to evaluate the diagnos-
tic signiﬁcance of blood ﬂow measured with this method. This is a
small explorative study suggesting the possibility to use cerebral
blood ﬂow estimated by early frame PIB data and their correlation
to changes in rCMRglc. In order to test this hypothetical correlation
we are utilising a data set with quite large variation in parameters
in order to measure correlations. If the material had been divided
into different individual groups we probably would have lost these
correlations. In this study we do not draw any conclusions that ePIB
can be used to show disease progression or to distinguish different
patient groups. Although FDG-PET still is the method of choice to
evaluate functional decline in brain the results in this study neverthe-
less it indicates that a single dynamic PIB PET may provide valuable
information about pathological and physiological changes (amyloid-
osis and impaired blood ﬂow) in AD. Such dual information could
be used to better understand the pathology of dementia diseases
hopefully contributing to improve future differential diagnosis also
making it more cost effective with the need of only one PET scan.
Clinical amyloid imaging will most probably be used as biomarkers
when 18F amyloid ligands will be clinically available. The new pro-
posals of revised diagnostic criteria of AD from European efforts as
well as the National Institute of Aging and Alzheimer's Association
[49–53] suggest amyloid imaging as the early biomarker for prodro-
mal AD. The use of these amyloid ligands as dual markers for both
amyloid and functional (neuronal) changes will provide valuable
clinical insight into the functional progression of the AD disease.Acknowledgements
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